<DOC>
	<DOC>NCT02173184</DOC>
	<brief_summary>To investigate the efficacy (therapeutic response) of Gynevac vaccination following a 5-shot treatment period in patients with bacterial vaginosis, based on the Nugent Score and the Amsel criteria</brief_summary>
	<brief_title>Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult premenopausal females, 18 years and older. Mentally competent patients that can comply with the study protocol and are able to complete and keep or study related material (patient diaries, etc.). Signed and dated written informed consent. Clinical diagnosis of BV according to Amsel criteria Gram stains Nugent Score â‰¥7 or Nugent Score 46 with the presence of clue cells Patient does not need an antiinfective treatment which would be required for specific treatment of vaginosis or to prevent the development of acute vaginitis and which may affect treatment outcome of BV. Negative pregnancy test at screening. Patients with other infectious causes of vulvovaginitis (e.g. Vaginal candidiasis, Trichomonas vaginalis). Patients with another vaginal or vulvar condition, which would confound the interpretation of clinical and or therapeutic response. Patients who received antifungal or antimicrobial therapy (systemic or intravaginal), as part of standard clinical practice, or clinical trial, within 14 days of randomization. Patients who are diagnosed with a chronic inflammatory disease (Rheumatoid Arthritis, psoriasis, Crohn's disease, Coeliac disease, spondyloarthritis rheumatica etc.) Women who are scheduled to be under treatment during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma. Pregnancy or lactation. Patients with known hypersensitivity to formaldehyde. Patients undergoing antibiotic treatment. Patients with acute polyarthritis, known serious cardiac, liver, kidney diseases or unstable diabetes mellitus. Known abnormalities of the blood circulation or of the haemopoietic system. Use of any investigational drug within 30 days from randomization. Patients who do not abstain from use of intravaginal products for at least 7 days prior to study randomization (e.g. douches, female deodorant sprays, spermicides, condoms, tampons, and diaphragms). Patients should also refrain from using intravaginal products 3 days prior to each study visit. Patients who do not abstain from vaginal intercourse during at least 3 days prior to each study visit.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>bacterial vaginosis</keyword>
	<keyword>Gynevac Lactobacillus vaccine</keyword>
</DOC>